The Muscle Problem GLP-1s Can't Solve: Why Exercise After Weight Loss Still Wins

The study, published in Obesity in 2026, followed 195 adults who had just lost an average of 13.1 kg on a low-calorie diet. Researchers then randomized them to one of four paths for a full year: usual activity, a structured program of moderate-to-vigorous exercise, the GLP-1 receptor agonist liraglutide at 3.0 mg per day, or exercise plus the drug. The question was narrow but consequential — would any of these maintenance strategies change how much GLP-1 the body itself secretes after a meal?

The answer was striking in its asymmetry. After a year, the exercise group's late-phase postprandial GLP-1 response had climbed by 37%, a within-group increase of 25% over those doing usual activity. In the groups taking the GLP-1 drug, by contrast, endogenous secretion was unchanged versus placebo. The medication mimics the hormone; it does not appear to train the gut to make more of it.

That distinction matters because the late-phase postprandial GLP-1 signal is part of how the body naturally tells itself the meal is over. A larger endogenous response after eating is one plausible mechanism by which exercise may blunt the appetite rebound that so often follows weight loss — the biological undertow that drags people back toward their starting weight. The trial's authors are careful to frame this as exploratory, and the readout is a hormonal response rather than a long-term weight outcome, but the directional finding is consistent and biologically coherent.

The exercise finding lands at the same moment a second, quieter conversation is gathering force in the clinical literature: what GLP-1 and dual GIP/GLP-1 drugs may be doing to muscle, particularly in older adults. A 2025 perspective in Diabetes walks through the emerging concern around sarcopenic obesity — a condition the authors note affects an estimated 28.3% of people aged over 60 — and how the new drug class intersects with it.

The perspective is not anti-medication. It credits incretin therapies with meaningful reductions in weight, improvements in physical function, and gains in quality of life. But it flags a real trade-off: rapid pharmacologic weight loss carries the risk of loss of muscle mass and an increased rate of adverse events, especially in older patients whose muscle reserves are already thinning with age. The authors urge clinicians to weigh benefits against those risks and to think carefully about patient identification, monitoring, and how — and when — to discontinue.

Read together, the two papers point in the same direction. The drugs are powerful tools for getting weight off. Exercise looks increasingly necessary for keeping it off in a body that still works the way you want it to.

It is worth being precise about the scope. The exercise finding comes from an exploratory analysis, not the trial's primary weight-maintenance endpoint, and the measured outcome was the GLP-1 response to a three-hour liquid mixed meal test, not a head-to-head verdict on long-term weight regain. The intervention itself was substantial — 52 weeks of moderate-to-vigorous activity — not a casual uptick in step count. And the comparator drug was liraglutide at 3.0 mg, an earlier-generation GLP-1 agonist; the newer, more potent agents (semaglutide, tirzepatide) were not tested here.

None of that erases the signal. It does mean the right way to talk about it is as a plausible, biologically grounded mechanism that fits with a wider body of work on exercise and appetite regulation — not as proof that exercise beats the drugs on weight outcomes. The evidence is moderate, and the language should be too.

For readers already on an incretin, none of this argues for stopping. It argues for pairing. The clinical concern about muscle is loudest in older adults and in anyone losing weight quickly, and the obvious counterweight — resistance training plus adequate protein, alongside aerobic work — is the same advice that holds up across most of the maintenance literature. The new trial adds a second reason to take it seriously: the exercise itself may be doing hormonal work the drug isn't.

For readers considering the drugs, the framing shift is subtle but important. Exercise has often been pitched as the thing you do instead of medication, or the thing you graduate to once the medication has done its job. The emerging picture is closer to the opposite: exercise is the substrate the medication is built on top of, and the part most likely to determine what the body looks and functions like a year or five years from now.

As always, these are conversations to have with a clinician who knows your history — including how fast you're losing weight, what your baseline muscle and function look like, and what you want the next decade of your life to feel like. The drugs are real medicine. So, in a quieter and less marketable way, is the squat rack.